According to MeiraGTx's latest financial reports the company's current revenue (TTM ) is NZ$57.9 Million. In 2024 the company made a revenue of NZ$59 Million an increase over the revenue in the year 2023 that were of NZ$22.16 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2025 (TTM) | NZ$58.98 M | -0.05% |
2024 | NZ$59 M | 166.23% |
2023 | NZ$22.16 M | -11.61% |
2022 | NZ$25.07 M | -54.57% |
2021 | NZ$55.19 M | 155.89% |
2020 | NZ$21.57 M | 9.29% |
2019 | NZ$19.73 M | |
2018 | N/A | |
2017 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Novocure
NVCR | NZ$1.04 B | 1,701.64% | Jersey |
![]() Novavax NVAX | NZ$2.03 B | 3,419.88% | ๐บ๐ธ USA |
![]() Organovo ONVO | NZ$0.24 M | -99.58% | ๐บ๐ธ USA |
![]() Orchard Therapeutics
ORTX | NZ$36.64 M | -36.71% | ๐ฌ๐ง UK |